Emergent BioSolutions Inc. Form 4 (Feb. 24, 2021) — El-Hibri

Summary

A Form 4 for Emergent BioSolutions Inc. [EBS] reports grants on February 24, 2021, to El-Hibri Fuad, marked as a director and as an officer with the title Chairman. The reporting person received 27,808 Employee Stock Options (Right to Buy) with a $93.49 exercise price, expiring 02/23/2031, and 13,906 restricted stock units, which convert into common stock on a one-for-one basis. The explanation of responses says both grants vest in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date. The form is signed /s/ Carl A. Valenstein, attorney-in-fact, on February 26, 2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * El-Hibri Fuad (Last) (First) (Middle) 400 PROFESSIONAL DRIVE, SUITE 400 (Street) GAITHERSBURG MD 20879 (City) (State) (Zip) | El-Hibri Fuad | (Last) | (First) | (Middle) | 400 PROFESSIONAL DRIVE, SUITE 400 | GAITHERSBURG | MD | 20879 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [ EBS ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) Chairman | X | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | Chairman
3. Date of Earliest Transaction
 (Month/Day/Year) 02/24/2021
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Employee Stock Options (Right to Buy) | $ 93.49 | 02/24/2021 | A | 27,808 | (2) | 02/23/2031 | Common Stock | 27,808 | $ 0.00 | 27,808 | D
Restricted Stock Unit | (1) | 02/24/2021 | A | 13,906 | (3) | (3) | Common Stock | 13,906 | $ 0.00 | 13,906 | D
Explanation of Responses:
1. Restricted stock units convert into common stock on a one-for-one basis.
2. On February 24, 2021, Mr. El-Hibri was granted 27,808 stock options vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date.
3. On February 24, 2021, Mr. El-Hibri was granted 13,906 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date.
Remarks:
/s/ Carl A. Valenstein, attorney-in-fact | 02/26/2021
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_EBS_4_filed2021-02-26_0000899243-21-008483.xml

Size

17,078 bytes

SHA-256

31c76c2b9f4627fd3bab9857877b757db7265dab73aac8fc783fc35471de7a4c

Our copy

SEC_EBS_4_filed2021-02-26_0000899243-21-008483.xml

Original

www.sec.gov